Co-formulation of broadly neutralizing antibodies 3BNC117 and PGT121:Analytical challenges during pre-formulation characterization and storage stability studies by Patel, Ashaben et al.
CO-FORMULATION OF BROADLY NEUTRALIZING ANTIBODIES 3BNC117 AND PGT121: 
ANALYTICAL CHALLENGES DURING PRE-FORMULATION CHARACTERIZATION AND STORAGE 
STABILITY STUDIES* 
 
Ashaben Patel, University of Kansas 
Vineet Gupta, University of Kansas 
vineet.gupta@ku.edu 
John M. Hickey, University of Kansas 
Nancy S. Nightlinger, Just Biotherapeutics Inc. 
Richard S. Rogers, Just Biotherapeutics Inc. 
Christine Siska, Just Biotherapeutics Inc. 
Sangeeta B. Joshi, University of Kansas 
Bruce A. Kerwin, Just Biotherapeutics Inc. 
David B. Volkin, University of Kansas 
 
 
Key Words: Broadly neutralizing antibodies, Co-formulation, Stability, Protein aggregation 
 
In this study, we investigated analytical challenges associated with the formulation of two broadly neutralizing 
anti-HIV monoclonal antibodies (bnAbs), 3BNC117 and PGT121, both separately at 100 mg/mL and together at 
50 mg/mL each. The bnAb formulations were characterized for relative solubility and conformational stability 
followed by accelerated and real-time stability studies. While the bnAbs were stable during 4°C storage, 
incubation at 40°C differentiated their stability profiles. Specific concentration dependent aggregation rates at 
30°C and 40°C were measured by size exclusion chromatography for the individual bnAbs with the mixture 
showing intermediate behavior. Interestingly, while the relative ratio of the two bnAbs remained constant at 4°C, 
the ratio of 3BNC117 to PGT121 increased in the dimer that formed during storage at 40°C. A mass 
spectrometry based multi-attribute method (MAM), identified and quantified differences in modifications of the 
Fab regions for each bnAb within the mixture including clipping, oxidation, deamidation and isomerization sites. 
Each bnAb showed slight differences in the levels and sites of lysine residue glycations. Together, these data 
demonstrate the ability to differentiate degradation products from individual antibodies within the bnAb mixture, 
and that degradation rates are influenced not only by the individual bnAb concentrations but also by the mixture 
concentration. 
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